- Home
- YETI vs RCUS Comparison
YETI vs RCUS Comparison
Compare YETI & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YETI | RCUS |
|---|---|---|
| Founded | 2006 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.6B |
| IPO Year | 2016 | 2018 |
Fundamental Metrics
Financial Performance| Metric | YETI | RCUS |
|---|---|---|
| Price | $50.92 | $27.84 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 10 |
| Target Price | ★ $47.75 | $31.90 |
| AVG Volume (30 Days) | 1.0M | ★ 1.0M |
| Earning Date | 05-14-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.13 | N/A |
| Revenue | ★ $1,868,494,000.00 | $247,000,000.00 |
| Revenue This Year | $9.07 | N/A |
| Revenue Next Year | $7.11 | $45.62 |
| P/E Ratio | $387.54 | ★ N/A |
| Revenue Growth | ★ 2.11 | N/A |
| 52 Week Low | $30.51 | $8.84 |
| 52 Week High | $53.21 | $31.74 |
Technical Indicators
Market Signals| Indicator | YETI | RCUS |
|---|---|---|
| Relative Strength Index (RSI) | 57.68 | 50.11 |
| Support Level | $43.59 | $19.78 |
| Resistance Level | $53.21 | $28.72 |
| Average True Range (ATR) | 1.76 | 1.39 |
| MACD | 0.03 | -0.20 |
| Stochastic Oscillator | 67.65 | 46.21 |
Price Performance
Historical ComparisonAbout YETI YETI Holdings Inc.
YETI Holdings Inc is a designer, marketer, and distributor of premium products for the outdoor and recreation market sold under the YETI brand. The company offers products including coolers and equipment, drinkware, and other accessories. Its trademark products include YETI Tundra, Hopper, YETI TANK, Rambler, Colster, Rambler among others. The company distributes products through wholesale channels and through direct-to-consumer, or DTC, channels.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.